Topical Corticosteroids Market

Topical Corticosteroids Market Size (2024 to 2029)

The global topical corticosteroids market is expected to reach USD 5.21 Billion by 2029 from USD 4.06 Billion in 2024, with a CAGR of 5.12% from 2024 to 2029.

MARKET DRIVERS

The rise in skin complications is one of the major factors propelling the growth of the global topical corticosteroids market due to lifestyle choices, a rise in pollution, and diet choices. There has been an increased prevalence of skin diseases such as acne, dermatitis, psoriasis, skin infection, hyperpigmentation, melasma, and others due to its anti-inflammatory effect. Both the Young and geriatric populations are susceptible to these skin diseases, however, the elderly population is likely to be more prone to some of these diseases, like eczema and dermatitis, due to aging. In 2020, it was found that about 31.6 million Americans had eczema, with 15% of children and 7.3% of adults affected by atopic dermatitis annually.

The growing investments from the key market participants to conduct topical corticosteroids fuel the market’s growth rate. Research and development efforts in the different formulations of corticosteroids have seen a rise in recent days. Due to the rise in cases of the mentioned skin diseases, there is an increasing awareness among patients and doctors of topical Corticosteroids and their uses, as most topical corticosteroids can be purchased over the counter.

MARKET RESTRAINTS

The side effects attributed due to long-term usage are one of the major factors hampering the global market growth. While these medications are generally safe and effective when used as prescribed and according to the dosage, they may have some potential side effects, especially with prolonged usage. The side effects include stretch marks and skin thinning, which make skin fragile and susceptible to bruises, which can get infected, spreading the skin disease even more. Some corticosteroids may also cause hyperpigmentation. This has led to alternatives in the market, such as antihistamines and natural remedies. These alternatives are also cost-effective, but corticosteroids are not in some prescribed formulations.

Impact of COVID-19 on the topical corticosteroids market

The global topical corticosteroids market had a significant impact due to the COVID-19 pandemic. The Supply chains were disrupted during the COVID-19 pandemic and drug manufacturing companies focused more on drugs that were directly related to the symptoms of the COVID-19 virus. The disruption in supply chains also caused delays in the raw material logistics and resulted in increased prices of topical corticosteroids. However, in the later stages of the COVID-19 pandemic, due to allergies and constant wearing of masks, there was an increase in skin rashes, dermatitis, and acne and fuelled the demand for topical corticosteroids and drove market growth. Overall, the COVID-19 pandemic had a mixed impact on the global topical corticosteroids market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Topical Corticosteroids Market Analysis By Molecule Name

Based on the molecule name, the fludroxycortide segment is anticipated to hold the major share of the global market during the forecast period. Fludroxycortide is a strong corticosteroid that is mainly used for its effective action against different types of dermatitis and psoriasis. It is an excellent anti-inflammatory and immunosuppressant and can be made synthetically.

Global Topical Corticosteroids Market Analysis By Application

The acne segment is predicted to account for the leading share of the global market during the forecast period. According to the National Institutes of Health, it has been estimated that around 9.4% of the world’s population has acne. Corticosteroids are extremely efficient at tackling Acne.

The dermatitis segment accounted for a considerable share of the global market in 2022 and is estimated to witness a healthy CAGR during the forecast period owing to the rise in dermatitis cases worldwide and the high effectiveness of Corticosteroids against Dermatitis.

Global Topical Corticosteroids Market Analysis By Medication Type

The creams segment dominated the market in 2022 and the domination of the segment in the global market during the forecast period. Creams are consistent, allowing them to be evenly spread over the affected area. Creams also contain water and have a soothing effect while also moisturizing the skin, which is suitable for most skin types.

Global Topical Corticosteroids Market Analysis By Distribution Channel

Based on the distribution channel, the hospital pharmacies segment had the largest share of the global market during the forecast period. Because patients directly get the prescribed medications from the hospital pharmacies after the diagnosis. These hospital pharmacies have a wide range of corticosteroids available.

The retail pharmacies segment is anticipated to account for the second largest share of the worldwide market during the forecast period. Increased awareness and several commonly used Corticosteroids being categorized as OTC medicines primarily drive the growth of the retail pharmacies segment in the global market.

REGIONAL ANALYSIS

The North American region led the market in 2022 and is expected to account for the major share of the global topical corticosteroids market during the forecast period owing to the increasing awareness and the rise of skin diseases. The presence of several key market participants and developed economies such as the U.S. and Canada, the availability of investments for R&D activities and the increasing number of product launches further propel the growth of the North American market. 50 million people suffer from acne in the USA,

The Europe region ranks in second position and is growing at a rapid pace. An increase in the geriatric population as skin diseases are likely to affect the elderly, which is one of the primary factors propelling the European market. The European region also has developed healthcare systems and high disposable income with high government backing for research and development efforts, which are further contributing to the growth of the European topical corticosteroids market.

The Asia-Pacific regional market is predicted to be the most lucrative regional market and register a promising CAGR among all regions in the worldwide market. The lifestyle and diet changes and rapid adoption of sedentary lifestyles across the Asia-Pacific region majorly drive the growth of the APAC market. Countries such as India, China, South Korea and Japan are expected to hold the major share of the APAC market in the coming years. The presence of key market players in the Asia Pacific contributes to the APAC market growth. For instance, Lupin Limited, an Indian pharmaceutical company, launched its US Food and Drug Administration (FDA) approved product Fluocinonide Ointment USP, 0.05% in the Market. Fluocinonide is a potent topical corticosteroid used for the treatment of various skin conditions like eczema, psoriasis, dermatitis, and other inflammatory skin disorders.

Latin America ranks at fourth in the global topical corticosteroids market, growing geriatric population and developing healthcare infrastructure are likely to cause a steady CAGR.

Middle East & Africa hold a small number of shares in the global market, and the regions are expected to develop and grow during the forecast period.

KEY PLAYERS IN THE GLOBAL TOPICAL CORTICOSTEROIDS MARKET

Gsk plc (U.K.), Almirall, S.A (Spain), Merck & Co., Inc. (Germany), Bausch Health (Canada), Sandoz International GmbH (Germany), Pfizer Inc. (U.S.), AstraZeneca (U.K.), Sanofi (France), Bayer AG (Germany), McKesson Corporation (U.S.), Regeneron Pharmaceuticals Inc. (U.S.), Medtronic (Ireland), AbbVie Inc. (U.S.), GALDERMA LABORATORIES, L.P. (U.S.), Novartis AG (Switzerland), LEO Pharma A/S (Denmark), Cipla Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Mylan N.V. (U.S.) are a few of the

RECENT HAPPENINGS IN THE MARKET

• In April 2022, Eli Lilly and Company, a global healthcare company, announced that Lebrikizumab, an IL-13 inhibitor, significantly improved the severity of atopic dermatitis (AD) in people with moderate-to-severe AD when combined with topical corticosteroids (TCS). This finding was based on the third pivotal Phase 3 trial (ADhere).
• In 2021, Rinvoq launched its FDA-approved Upadacitinib for the treatment of moderate-to-severe plaque psoriasis. Upadacitinib topical JAK inhibitor. Rinvoq is applied as a cream once daily and is designed to reduce inflammation and improve skin lesions significantly.

DETAILED SEGMENTATION OF THE TOPICAL CORTICOSTEROIDS MARKET INCLUDED IN THIS REPORT

The research report on the topical corticosteroids market has been segmented and sub-segmented the market by molecule name, application, medication type, distribution channel, and region.

By Molecule Name

• Fludroxycortide
• Triamcinolone Acetonide
• Fluocinolone Acetonide
• Betamethasone
• Clobetasone Propionate
• Clobetasone Butyrate
• Halobetasone
• Mometasone

By Application

• Acne
• Dermatitis
• Psoriasis
• Skin Infection
• Hyperpigmentation
• Melasma

By Medication Type

• Ointments
• Creams
• Liquid and Solutions
• Lotions
• Gel
• Oils
• Pastes
• Sprays

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East Africa